,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2016-10-18 05:55:00,Johnson & Johnson (NYSE: JNJ ) shareholders are waking up with a shrug today.,0.19657018780708313,0.10349493473768234,0.6999348998069763,neutral,0.09307525306940079
1,2016-10-18 05:55:00,"JNJ stock is slightly off after the thinnest of earnings beats, with the save coming from the company's pharmaceutical business.",0.02787526324391365,0.9429823756217957,0.02914227731525898,negative,-0.9151071310043335
2,2016-10-18 05:55:00,"For the quarter ended in September, JNJ earned $4.68 billion, or $1.68 per share, on revenues of $17.82 billion.",0.07900121062994003,0.031009694561362267,0.8899890780448914,neutral,0.04799151420593262
3,2016-10-18 05:55:00,"The consensus estimate had been for earnings of $1.65 per share, with a ""whisper number"" of $1.66.",0.26898810267448425,0.11267931759357452,0.61833256483078,neutral,0.15630878508090973
4,2016-10-18 05:55:00,Analysts expected $17.74 billion in revenues.,0.05821799486875534,0.006389489397406578,0.9353925585746765,neutral,0.05182850360870361
5,2016-10-18 05:55:00,"Moreover, Johnson & Johnson maintained sales guidance for full-year 2016 of $71.5 billion to $72.2 billion, though it increased its adjusted earnings guidance for full-year 2016 to $6.68 to $6.73 per share.",0.8630046248435974,0.03152066096663475,0.10547472536563873,positive,0.8314839601516724
6,2016-10-18 05:55:00,"Johnson & Johnson stock, however, was unfazed.",0.10551512986421585,0.47304654121398926,0.4214383363723755,negative,-0.367531418800354
7,2016-10-18 05:55:00,"Analysts had become accustomed to JNJ beating earnings estimates, and this upside surprise was the smallest since last December.",0.05172166973352432,0.9218639731407166,0.0264144130051136,negative,-0.8701422810554504
8,2016-10-18 05:55:00,Though it is twice the company's newly raised dividend of 80 cents per share.,0.5848677754402161,0.08289776742458344,0.3322344720363617,positive,0.5019699931144714
9,2016-10-18 05:55:00,"In its earnings release, Johnson & Johnson acknowledged that pharmaceutical products are the star of its show, with sales up 9.2% over a year ago.",0.9481343030929565,0.018075736239552498,0.033789895474910736,positive,0.9300585389137268
10,2016-10-18 05:55:00,"Cancer drugs and medicines heavily advertised on TV - such as Xarelto, an anti-coagulant whose ads starred the late Arnold Palmer, and Stelara, an immunosuppressant currently advertised for treatment of psoriasis, but recently approved for treatment of Crohn's Disease - helped the cause.",0.31437861919403076,0.05675129219889641,0.6288700699806213,neutral,0.25762733817100525
11,2016-10-18 05:55:00,"• 7 Stocks to Buy That Will Grow by Double Digits

The FDA approval on Crohn's disease is likely to hike the ad budget for Stelara.",0.7664192318916321,0.13505102694034576,0.09852974116802216,positive,0.6313682198524475
12,2016-10-18 05:55:00,"It will now compete more directly with Humira from AbbVie Inc (NYSE: ABBV ), which generated $14 billion in sales in 2015 as a treatment for Crohn's and rheumatoid arthritis.",0.7687503099441528,0.011139167472720146,0.2201104611158371,positive,0.7576111555099487
13,2016-10-18 05:55:00,"Johnson & Johnson also has another rheumatoid arthritis drug, sirukumab, going through the regulatory process.",0.08428028970956802,0.007761861197650433,0.9079578518867493,neutral,0.07651843130588531
14,2016-10-18 05:55:00,"In addition to being heavily advertised, drugs to cure autoimmune diseases like Crohn's, psoriasis and rheumatoid arthritis continue to be a key focus of research .",0.1209445670247078,0.006993521470576525,0.8720619678497314,neutral,0.11395104229450226
15,2016-10-18 05:55:00,So a business risk is that they will be replaced by better drugs before their patents expire.,0.04148375615477562,0.26180022954940796,0.6967159509658813,neutral,-0.22031646966934204
16,2016-10-18 05:55:00,"Thus immunosuppressant drugs such as Humira, Stelara and Otezla from Celgene Corporation (NASDAQ: CELG ) are in heavy ad rotation to generate sales quickly, despite the fact that since the drugs can be approved for treatment of several conditions, there is considerable market confusion.",0.553523600101471,0.17686514556407928,0.2696112096309662,positive,0.37665843963623047
17,2016-10-18 05:55:00,"The conditions they treat are often more implied than stated, since it's possible they could be used to treatment other conditions that consumers may see as unrelated.",0.021677596494555473,0.033295080065727234,0.9450273513793945,neutral,-0.01161748357117176
18,2016-10-18 05:55:00,This confusion demonstrates another risk for these drugs: the possibility that a new Clinton Administration may push either to instill greater price competition or controls on advertising to lower costs.,0.31928563117980957,0.18818975985050201,0.4925245940685272,neutral,0.13109587132930756
19,2016-10-18 05:55:00,"Outside the pharmaceutical business, JNJ stock is a slow-growth or no-growth prospect.",0.05636412650346756,0.149839386343956,0.7937964797019958,neutral,-0.09347525984048843
20,2016-10-18 05:55:00,"Its popular consumer brands - products like baby powder and shampoo - of $3.3 billion were down 1.6% against the prior year, and sales of its medical devices, $6.6 billion, increased just 1.1%.",0.0188739113509655,0.9714317917823792,0.009694281034171581,negative,-0.9525578618049622
21,2016-10-18 05:55:00,"The purchase of Abbott Medical Optics from Abbott Laboratories (NYSE: ABT ), for $4.325 billion, completed during the quarter, will help device sales going forward.",0.9437410235404968,0.01458537857979536,0.041673630475997925,positive,0.9291556477546692
22,2016-10-18 05:55:00,That company recently launched a balloon dilation treatment for expanding the eustachion tube that runs between the ear and the mouth.,0.5955093502998352,0.017172448337078094,0.38731813430786133,positive,0.5783368945121765
23,2016-10-18 05:55:00,"JNJ stock advanced over 15% in price so far this year, despite the fact that most analysts have it rated only as a hold , due to its single-digit growth.",0.9519748091697693,0.017384862527251244,0.03064027428627014,positive,0.9345899224281311
24,2016-10-18 05:55:00,This is the kind of company that investors can buy and hold if they don't care to read stories like this one.,0.038689568638801575,0.00801121722906828,0.9532992243766785,neutral,0.03067835047841072
25,2016-10-18 05:55:00,"Dana Blankenhornis a financial journalist who dabbles in fiction, his latest beingThe Reluctant Detective Travels in Time .",0.09491704404354095,0.06857886910438538,0.8365040421485901,neutral,0.02633817493915558
26,2016-10-18 05:55:00,"Write him at danablankenhorn@gmail.comor follow him on Twitter at @danablankenhorn .As of this writing, he did not hold a position in any of the aforementioned securities.",0.009094707667827606,0.03216773644089699,0.9587374925613403,neutral,-0.02307302877306938
27,2016-10-18 05:55:00,"• Home Depot Inc (HD) Stock Is Threatening to Fail You
• 10 Stocks That Every Investor Should Own

The post Without Drugs, Johnson & Johnson Has Nothing (JNJ) appeared first on InvestorPlace .",0.14151765406131744,0.10773269832134247,0.7507496476173401,neutral,0.033784955739974976
28,2016-10-18 05:55:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
